Salix Pharmaceuticals has received a subpoena from the U.S. Attorney's Office for the Southern District of New York requesting documents related to the Raleigh company's sales and promotional practices for three of its drugs.
The company received the subpoena on Feb. 1, according to a regulatory filing Salix filed Tuesday.
The drugs involved include Salix's best selling drug, Xifaxan, as well as Relistor and Apriso.
Salix said in its filing that it is in the process of responding to the subpoena and intends to cooperate fully with the investigation.
"The company cannot predict or determine the impact of this inquiry on our financial condition or results of operations," the company said in its filing.
Michael Freeman, a Salix spokesman, said Wednesday that the company would have no comment beyond what was in its regulatory filing.